Landing
International Conference on Pharmacoepidemiology (ICPE) 2023
Healthcare Resource Utilization from OPERA: a Real-World Study of Pegcetacoplan Treatment in US Adults with Paroxysmal Nocturnal Hemoglobinuria
Comparative Effectiveness of Pegcetacoplan (PEG) Versus Ravulizumab (RAV) and Eculizumab (ECU) in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): A Matching-Adjusted Indirect Comparison
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.